Where Does CRON Stock Rank in the Drug Manufacturers - Specialty & Generic Industry?

Wednesday, November 20, 2019 1:38 PM | InvestorsObserver Analysts

The 41 rating InvestorsObserver gives to Cronos Group Inc (CRON) stock puts it near the top of the Drug Manufacturers - Specialty & Generic industry. In addition to scoring higher than 77 percent of stocks in the Drug Manufacturers - Specialty & Generic industry, CRON’s 41 overall rating means the stock scores better than 41 percent of all stocks.

Click Here to get the full Stock Score Report on Cronos Group Inc (CRON) Stock.

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 41 means the stock is more attractive than 41 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Cronos Group Inc Stock Today?

Cronos Group Inc (CRON) stock is higher by 2.39% while the S&P 500 is lower by -0.83% as of 1:35 PM on Wednesday, Nov 20. CRON is higher by $0.16 from the previous closing price of $6.70 on volume of 13,466,570 shares. Over the past year the S&P 500 has risen 17.12% while CRON is lower by -16.34%. CRON lost -$0.02 per share the over the last 12 months.

To see the top 5 stocks in Drug Manufacturers - Specialty & Generic click here.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Should Zogenix, Inc. (ZGNX) be in Your Portfolio?

Is Sundial Growers Inc (SNDL) a Winner in the Drug Manufacturers - Specialty & Generic Industry?

Is FibroGen Inc (FGEN) Stock Near the Top of the Biotechnology Industry?

Is Ligand Pharmaceuticals Inc. (LGND) a Winner in the Biotechnology Industry?

Where Does EXACT Sciences Corporation (EXAS) Stock Fall in the Diagnostics & Research Field?

Related Companies